Yidu Tech Inc. 醫渡科技有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code 股份代號：2158) N O T I F I C AT I O N L E T T E R 通 知 信 函 30 December 2025 Dear Non-registered holders(Note 1) Yidu Tech Inc. (the "Company") – Notice of Publication of 2026 Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website of The Stock Exchange of Hong Kong ...

Yidu Tech Inc. 醫渡科技有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code 股份代號：2158) N O T I F I C AT I O N L E T T E R 通 知 信 函 30 December 2025 Dear Registered Shareholders, Yidu Tech Inc. (the "Company") – Notice of Publication of 2026 Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website of The Stock Exchange of Hong Kong Limite ...

（於開曼群島註冊成立的有限公司） (incorporated in the Cayman Islands with limited liability) Stock code 股份代號: 2158 2025/26 中期報告 Interim Report Yidu Te ch In c. 醫渡科技有限公 司 Interim Report 2025/26 中期報告 目錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 5 | | 業務回顧 | 6 | | 管理層討論及分析 | 14 | | 企業管治及其他資料 | 19 | | 中期財務資料審閱報告 | 33 | | 中期簡明合併綜合收益表 | 35 | | 中期簡明合併資產負債表 | 37 | | 中期簡明合併權益變動表 | 39 | | 中期簡明合併現金流量表 | 40 | | 中期簡明合併財務資料附註 | 41 | | 釋義 | 77 | 公司資料 執行董事 宮盈盈女士 （董事長） 徐濟銘先生 （首席執行官） 封曉瑛女士 謝麗女士 非執行董事 曾鳴先生 獨立非執行董事 馬維英博士 潘蓉容女士 張林琦教授 審核委員會 潘蓉容女士 （主席 ...

Core Viewpoint - Yidu Technology has been invited to participate in the Henan Provincial Health Industry Development Conference and has signed on as one of the first partners of the National Artificial Intelligence Application Pilot Base (Medical Direction), marking a strategic move in the development of AI in healthcare in China [1][3]. Group 1: Strategic Partnerships and Collaborations - Yidu Technology is positioned as a "core co-builder" of national medical AI innovation, actively participating in the construction of two national AI pilot bases in Beijing and Henan [1][4]. - The collaboration includes partnerships with major tech companies like Baidu and Alibaba, as well as local medical institutions, to create a synergistic ecosystem that integrates technology, data, clinical applications, and AI [3][4]. Group 2: Objectives and Services of the Pilot Base - The National AI Application Pilot Base aims to provide comprehensive pilot services for medical AI products, including algorithm validation, clinical evaluation, and compliance declaration, to accelerate the industrialization of innovative results [3][4]. - Yidu Technology will focus on integrating AI with traditional Chinese medicine, leveraging its expertise in medical data governance and clinical research to support the development of intelligent applications in this field [4][5]. Group 3: Technological Capabilities and Achievements - Yidu Technology has developed the "AI Medical Brain" YiduCore, which has processed nearly 7 billion authorized medical records and collaborates with over 10,000 hospitals, providing a solid foundation for AI model training and optimization [5]. - The company emphasizes its commitment to independent innovation and aims to leverage the pilot base as a strategic support to meet regional development needs while contributing to the "Healthy China 2030" initiative [5].

Core Viewpoint - Yidu Technology has been invited to participate in the Henan Health Industry Development Conference and has signed on as one of the first partners of the National Artificial Intelligence Application Pilot Base (Medical Direction), marking a strategic expansion in the AI healthcare sector [1][3]. Group 1: Strategic Partnerships and Initiatives - The establishment of the National AI Application Pilot Base in Zhengzhou is a key initiative for Henan Province to implement national health strategies and develop the future health industry [3]. - Yidu Technology is collaborating with major tech companies like Baidu and Alibaba, as well as local medical institutions, to create a synergistic ecosystem that integrates technology, data, clinical applications, and AI in healthcare [3][4]. Group 2: Technological Capabilities and Innovations - Yidu Technology's proprietary "AI Medical Brain" YiduCore has processed nearly 7 billion authorized medical records, covering over 10,000 hospital partnerships, providing a solid foundation for AI model training and clinical insights [5]. - The company aims to leverage its experience in AI and data governance to support the integration of AI with traditional Chinese medicine, enhancing the quality of healthcare services in the region [4][5]. Group 3: Future Development and Goals - Yidu Technology plans to continue its focus on independent innovation and align its AI research and implementation with regional development needs, contributing to the "Healthy China 2030" initiative [5].

Group 1 - Company repurchased 93,500 shares at HKD 5.23 per share on December 19, totaling approximately HKD 490,000, with a cumulative repurchase of about 3.44 million shares in December, amounting to over HKD 17.4 million [1] - The repurchase actions reflect the company's confidence in its future development and aim to strengthen market confidence [1] - The founder and chairman of the company, Gong Rujing, was appointed as a member of the advisory committee of the Digital Medicine Research Institute at City University of Hong Kong, indicating recognition from the industry and academia for the company's innovations in AI healthcare [1] Group 2 - The company has made significant strides in international cooperation, being selected as a member of the newly established Health Sustainable Development Working Committee of the Shanghai Cooperation Organization's multi-functional economic and trade platform [1] - The co-founder and CEO, Xu Jiming, was elected as the first council member of the committee, highlighting the company's professional capabilities and authoritative recognition in the international digital health cooperation field [1] - The company's international strategy has expanded its business and client network to six global regions, establishing a mature localized cooperation ecosystem through collaboration with local governments, medical institutions, and research institutes [2]

Group 1 - The Shanghai Cooperation Organization (SCO) has officially established the Health Sustainable Development Working Committee, with Yidu Tech (2158.HK) being recognized as a member due to its success in the international digital health sector [1] - Yidu Tech's co-founder and CEO, Xu Jiming, has been elected as the first director of the committee, marking a significant step in the company's involvement in international health cooperation and sustainable global health development [1] - The SCO's multi-functional economic platform aims to enhance cooperation in the health sector among member states, which has become a key consensus among the heads of state of the SCO [1] Group 2 - Wang Luo, director of the International Development Cooperation Research Institute of the Ministry of Commerce, emphasized the strategic significance of the pharmaceutical industry's international expansion and proposed a shift from "single-point blood transfusion" to "system empowerment" in foreign aid models [3] - Yidu Tech has been steadily advancing its international strategy, expanding its business and client network to six global regions, and has established a mature localized cooperation ecosystem through collaboration with local governments and healthcare institutions [3] - The company provides comprehensive digital health services and technical support in critical areas such as infectious disease monitoring, population health management, AI-assisted diagnosis, and personalized health management [3] Group 3 - Yidu Tech plans to leverage the SCO's multi-functional economic platform to enhance technical exchanges, project cooperation, and standard building in the health sector among member countries [4] - The company aims to inject digital momentum into the high-quality development of health services in SCO countries by providing mature intelligent solutions and supporting regional healthcare talent cultivation [4]

体验三大升级：让临床试验参与"省心又安心" 本次新上线的CTMS小程序是以试验参与者体验为出发点，实现从"管理导向"向"服务导向"的升级突 破，其深度融入微信生态，在移动端场景下为试验参与者带来了诸多便利： 参与更便捷。试验参与者无需下任何APP，通过微信小程序即可一键查询试验动态：访视时间、地点、 检查项目提前知晓，补贴报销进度实时可查，还能接收智能提醒，此外，小程序已无缝对接北肿的 DTP(药物直达)系统， 让试验参与者能够通过同一入口便捷获取试验相关药品服务，大幅降低了参与门 槛，提供了更贴心的服务体验。 沟通更安全。关键沟通均通过企业微信官方渠道进行，检查报告、试验方案等关键医疗资料通过CTMS 平台加密传输，数据安全可控，规避非官方渠道流转风险。 体验更连贯。借助企业微信自带功能，当CRC人员发生变动时，既往沟通记录、项目信息将实现无缝交 接，避免试验参与者重复沟通、信息对接不畅等问题，让试验过程始终连贯顺畅，减少试验参与者参与 负担和沟通成本。 如何让复杂的临床试验对参与者更"友好"，对管理者更"高效"？动动手指，临床试验的访视安排、报销 进度、用药服务即可一键掌握——这已不再是设想。近日，医渡科 ...

同时值得关注的是，医渡科技在国际多边合作舞台实现重要突破：上海合作组织国家多功能经贸平台 (上合家园)卫生可持续发展工作委员会近期正式成立，医渡科技成功入选组织成员单位;公司联合创始 人、CEO 徐济铭当选委员会第一届理事，双重认可标志着公司在国际数字健康合作领域的专业能力与 行业地位获得权威背书。 近年来，医渡科技的国际化战略布局稳步推进，业务和客户网络已拓展至全球六个地区。通过与当地政 府部门、医疗机构及科研院所深度协同，构建起了成熟的本土化合作生态，研发的智能化解决方案已广 泛落地于传染病监测预警、全民人口健康管理、AI 辅助诊疗、个性化健康管理等关键领域，持续以科 技力量赋能全球健康事业发展。 智通财经APP获悉，12月19日，医渡科技(02158)公告显示，当日以每股5.23港元的价格回购9.35万股， 回购金额约49万港元。12月以来，公司已回购11次，累计回购约344万股，总金额超1740万港元。以真 金白银持续夯实市场信心，彰显医渡科技对自身发展前景的坚定看好。 消息面上，医渡科技近期在行业认可与国际合作领域捷报频传。在香港城市大学数码医学研究院周年大 会上，公司创始人、董事长宫如璟女士获聘为 ...

医渡科技(02158)发布公告，于2025年12月19日斥资48.95万港元回购9.35万股。 ...